JP7240812B2 - 多量体タンパク質の純度の決定 - Google Patents

多量体タンパク質の純度の決定 Download PDF

Info

Publication number
JP7240812B2
JP7240812B2 JP2017558949A JP2017558949A JP7240812B2 JP 7240812 B2 JP7240812 B2 JP 7240812B2 JP 2017558949 A JP2017558949 A JP 2017558949A JP 2017558949 A JP2017558949 A JP 2017558949A JP 7240812 B2 JP7240812 B2 JP 7240812B2
Authority
JP
Japan
Prior art keywords
antibody
ligand
antibodies
seq
modified ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017558949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528389A5 (https=
JP2018528389A (ja
Inventor
カティル ムスサミ
ジャン－カエ ルオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2018528389A publication Critical patent/JP2018528389A/ja
Publication of JP2018528389A5 publication Critical patent/JP2018528389A5/ja
Priority to JP2021092988A priority Critical patent/JP7137663B2/ja
Priority to JP2022139802A priority patent/JP2022171730A/ja
Application granted granted Critical
Publication of JP7240812B2 publication Critical patent/JP7240812B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/06—Illumination; Optics
    • G01N2201/061—Sources
    • G01N2201/06113—Coherent sources; lasers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44795—Isoelectric focusing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017558949A 2015-05-12 2016-05-11 多量体タンパク質の純度の決定 Active JP7240812B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021092988A JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定
JP2022139802A JP2022171730A (ja) 2015-05-12 2022-09-02 多量体タンパク質の純度の決定

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160341P 2015-05-12 2015-05-12
US62/160,341 2015-05-12
PCT/US2016/031899 WO2016183222A1 (en) 2015-05-12 2016-05-11 Multimeric protein purity determination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021092988A Division JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定

Publications (3)

Publication Number Publication Date
JP2018528389A JP2018528389A (ja) 2018-09-27
JP2018528389A5 JP2018528389A5 (https=) 2021-01-21
JP7240812B2 true JP7240812B2 (ja) 2023-03-16

Family

ID=56072452

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017558949A Active JP7240812B2 (ja) 2015-05-12 2016-05-11 多量体タンパク質の純度の決定
JP2021092988A Active JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定
JP2022139802A Pending JP2022171730A (ja) 2015-05-12 2022-09-02 多量体タンパク質の純度の決定

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021092988A Active JP7137663B2 (ja) 2015-05-12 2021-06-02 多量体タンパク質の純度の決定
JP2022139802A Pending JP2022171730A (ja) 2015-05-12 2022-09-02 多量体タンパク質の純度の決定

Country Status (10)

Country Link
US (3) US10520511B2 (https=)
EP (2) EP3885368A1 (https=)
JP (3) JP7240812B2 (https=)
AR (1) AR104610A1 (https=)
AU (2) AU2016261854B2 (https=)
CA (1) CA2984010A1 (https=)
ES (1) ES2881359T3 (https=)
MA (2) MA56416A (https=)
PL (1) PL3294775T3 (https=)
WO (1) WO2016183222A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434629A3 (en) 2015-11-30 2024-12-25 Intabio, Llc Methods for sample characterization
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
DK3668985T3 (da) 2017-08-17 2021-09-20 Just Evotec Biologics Inc Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
CA3081094A1 (en) 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
WO2019148198A1 (en) 2018-01-29 2019-08-01 Intabio, Inc. Devices, methods and kits for sample characterization
EP3811397B1 (en) 2018-05-31 2024-09-18 Intabio, Llc Methods for interfacing microfluidic systems with mass spectrometry
PL3837282T3 (pl) * 2018-09-10 2026-02-16 Genentech, Inc. Układy i sposoby elektroforezy kapilarnej powinowactwa
US11573226B2 (en) 2018-09-10 2023-02-07 Genentech, Inc. Systems and methods for affinity capillary electrophoresis
US11782023B2 (en) * 2018-12-19 2023-10-10 Regeneron Pharmaceuticals, Inc. Ce-western applications for antibody development
CA3126712A1 (en) * 2019-01-31 2020-08-06 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
US11285484B2 (en) 2019-08-12 2022-03-29 Intabio, Llc Multichannel isoelectric focusing devices and high voltage power supplies
US12594557B2 (en) 2019-08-12 2026-04-07 Intabio, Llc Isoelectric focusing devices and fixtures
EP4323761A1 (en) * 2021-04-14 2024-02-21 DH Technologies Development Pte. Ltd. Native fluorescence detection for protein analysis in capillary electrophoresis
JP2024544607A (ja) * 2021-11-25 2024-12-03 エフ． ホフマン－ラ ロシュ アーゲー 少量の抗体副産物の定量

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517407A (ja) 1998-06-02 2002-06-18 グラディポア・リミテッド 抗体の精製
JP2009139255A (ja) 2007-12-07 2009-06-25 Fujifilm Corp イムノクロマトグラフ方法
JP2015510764A (ja) 2012-03-13 2015-04-13 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
JP4723725B2 (ja) * 1999-04-20 2011-07-13 ターゲット ディスカバリー， インコーポレイテッド 代謝経路を分析するための方法
US6818112B2 (en) * 1999-04-20 2004-11-16 Target Discovery, Inc. Protein separation via multidimensional electrophoresis
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AUPQ743300A0 (en) * 2000-05-11 2000-06-01 Life Therapeutics Limited Separation of avian antibodies
SG106672A1 (en) 2002-03-08 2004-10-29 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
US20090134028A1 (en) * 2005-09-22 2009-05-28 Chemicals Evaluation And Research Institute Method of Estimating Effect of Test Chemical on Living Organisms
EP1803814A1 (en) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
CA2836873C (en) * 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2604624A1 (en) * 2011-12-13 2013-06-19 University College Dublin National University Of Ireland, Dublin Bowman-Birk protease Inhibitor (BBI) binding peptides, and uses thereof in the separation, detection or purification of BBI.
RU2014153674A (ru) 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
TW202423993A (zh) * 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
CA2919174A1 (en) * 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
US11261262B2 (en) * 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517407A (ja) 1998-06-02 2002-06-18 グラディポア・リミテッド 抗体の精製
JP2009139255A (ja) 2007-12-07 2009-06-25 Fujifilm Corp イムノクロマトグラフ方法
JP2015510764A (ja) 2012-03-13 2015-04-13 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｉｎｔｒｏｄｕｃｉｎｇ ＣａｐｔｕｒｅＳｅｌｅｃｔ Ａｆｆｉｎｉｔｙ Ｌｉｇａｎｄ Ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ，［ｏｎｌｉｎｅ］，２０１１

Also Published As

Publication number Publication date
AU2022203033B2 (en) 2025-06-26
AR104610A1 (es) 2017-08-02
US20170045527A1 (en) 2017-02-16
JP2022171730A (ja) 2022-11-11
CA2984010A1 (en) 2016-11-17
ES2881359T3 (es) 2021-11-29
JP2018528389A (ja) 2018-09-27
PL3294775T3 (pl) 2021-12-13
JP7137663B2 (ja) 2022-09-14
WO2016183222A1 (en) 2016-11-17
EP3885368A1 (en) 2021-09-29
US20200166522A1 (en) 2020-05-28
MA43987A (fr) 2018-12-19
EP3294775B1 (en) 2021-07-14
AU2022203033A1 (en) 2022-05-26
AU2016261854B2 (en) 2022-05-26
AU2016261854A1 (en) 2017-11-09
HK1252480A1 (zh) 2019-05-24
JP2021152544A (ja) 2021-09-30
MA56416A (fr) 2022-05-04
US10520511B2 (en) 2019-12-31
US12158473B2 (en) 2024-12-03
US20240280587A1 (en) 2024-08-22
WO2016183222A4 (en) 2017-01-05
EP3294775A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
JP7137663B2 (ja) 多量体タンパク質の純度の決定
JP2021152544A6 (ja) 多量体タンパク質の純度の決定
CN111491951B (zh) 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
KR20180034500A (ko) 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
JP2018525407A (ja) 低伝導率洗浄緩衝液を用いたアフィニティークロマトグラフィー精製方法
JP2024156725A (ja) 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム
HK40059237A (en) Multimeric protein purity determination
HK1252480B (en) Multimeric protein purity determination
ES3041610T3 (en) Systems and methods for affinity capillary electrophoresis
EP4136121B1 (en) Systems, materials, and methods for reversed-phase high performance liquid chromatography (rp-hplc) for monitoring formation of multi-specific molecules
EA045004B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
EA049572B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
EA050781B1 (ru) Способ и хроматографическая система для определения количества и чистоты мультимерного белка
EA047453B1 (ru) Способ и хроматографическая система для определения количества и чистоты мультимерного белка
HK40032929A (en) Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
HK40050332B (zh) 用於亲和毛细管电泳的系统和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210602

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210602

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210609

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210610

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210730

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210804

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220413

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220810

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220829

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20221227

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230111

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230206

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230306

R150 Certificate of patent or registration of utility model

Ref document number: 7240812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150